CONDUIT PHARMACEUTICALS INC. Quarterly Income Tax Expense (Benefit) in USD from Q2 2022 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Conduit Pharmaceuticals Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q2 2022 to Q2 2023.
  • Conduit Pharmaceuticals Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2023 was $213K, a 616% increase year-over-year.
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2023 $213K +$183K +616% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $36.6K Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-15
Q3 2022 $157K Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-07
Q2 2022 $29.7K Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.